-
1
-
-
35348967949
-
Medical management of brain tumor patients
-
DOI 10.1016/j.ncl.2007.07.015, PII S0733861907000813, Brain Tumors in Adults
-
Drappatz J, Schiff D, Kesari S, et al: Medical management of brain tumor patients. Neurol Clinics 25:1035-1071, 2007 (Pubitemid 47610811)
-
(2007)
Neurologic Clinics
, vol.25
, Issue.4
, pp. 1035-1071
-
-
Drappatz, J.1
Schiff, D.2
Kesari, S.3
Norden, A.D.4
Wen, P.Y.5
-
2
-
-
0023933181
-
Steroid-induced CT changes in patients with recurrent malignant glioma
-
Cairncross G, Macdonald DR, Pexman JH, et al: Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38:724-726, 1988
-
(1988)
Neurology
, vol.38
, pp. 724-726
-
-
Cairncross, G.1
Macdonald, D.R.2
Pexman, J.H.3
-
3
-
-
0001643813
-
Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery
-
Galicich JH, French LA: Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat 12:169-174, 1961
-
(1961)
Am Pract Dig Treat
, vol.12
, pp. 169-174
-
-
Galicich, J.H.1
French, L.A.2
-
4
-
-
0001908046
-
Use of dexamethasone in treatment of cerebral edema associated with brain tumors
-
Galicich JH, French LA, Melby JC: Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet 81:46-53, 1961
-
(1961)
Lancet
, vol.81
, pp. 46-53
-
-
Galicich, J.H.1
French, L.A.2
Melby, J.C.3
-
5
-
-
0036933003
-
Dexamethasone treatment in patients with brain metastases and primary brain tumors: Do the benefits outweigh the side-effects?
-
DOI 10.1007/s00520-001-0333-0
-
Hempen C, Weiss E, Hess CF: Dexamethasone treatment in patients with brain metastases and primary brain tumors: Do the benefits outweigh the side-effects? Support Care Cancer 10:322-328, 2002 (Pubitemid 36056287)
-
(2002)
Supportive Care in Cancer
, vol.10
, Issue.4
, pp. 322-328
-
-
Hempen, C.1
Weiss, E.2
Hess, C.F.3
-
6
-
-
0023250995
-
Corticosteroid toxicity in neuro-oncology patients
-
Weissman DE, Dufer D, Vogel V, et al: Corticosteroid toxicity in neuro-oncology patients. J Neuro-Oncology 5:125-128, 1987 (Pubitemid 17125234)
-
(1987)
Journal of Neuro-Oncology
, vol.5
, Issue.2
, pp. 125-128
-
-
Weissman, D.E.1
Dufer, D.2
Vogel, V.3
Abeloff, M.D.4
-
7
-
-
0013954524
-
The action of steroids and Triton X-100 upon phospholipid/cholsterol structures
-
Weissman G, Sessa G, Weissman S: The action of steroids and Triton X-100 upon phospholipid/cholsterol structures. Biochem Pharmcol 15: 1537-1551, 1966
-
(1966)
Biochem Pharmcol
, vol.15
, pp. 1537-1551
-
-
Weissman, G.1
Sessa, G.2
Weissman, S.3
-
8
-
-
0023257243
-
A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage
-
Hall ED, McCall JM, Chase RL, et al: A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage. J Pharmacol Exp Ther 242:137-142, 1987 (Pubitemid 17112271)
-
(1987)
Journal of Pharmacology and Experimental Therapeutics
, vol.242
, Issue.1
, pp. 137-142
-
-
Hall, E.D.1
McCall, J.M.2
Chase, R.L.3
-
9
-
-
0025947608
-
Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells
-
Audus KL, Guillot FL, Braughler JM: Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells. Free Radical Biol Med 11:361-371, 1991
-
(1991)
Free Radical Biol Med
, vol.11
, pp. 361-371
-
-
Audus, K.L.1
Guillot, F.L.2
Braughler, J.M.3
-
10
-
-
0038407615
-
Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists
-
Hillhouse EW, Grammatopoulos OK: Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13:436-444, 2002
-
(2002)
Trends Endocrinol Metab
, vol.13
, pp. 436-444
-
-
Hillhouse, E.W.1
Grammatopoulos, O.K.2
-
11
-
-
0037622756
-
Expression of CRF1 and CRF2 receptors in human cancers
-
DOI 10.1210/jc.2002-021853
-
Reubi JC, Waser W, Vale W, et al: Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88:3312-3320, 2003 (Pubitemid 36877510)
-
(2003)
Journal of Clinical Endocrinology and Metabolism
, vol.88
, Issue.7
, pp. 3312-3320
-
-
Reubi, J.C.1
Waser, B.2
Vale, W.3
Rivier, J.4
-
12
-
-
0021967251
-
Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications
-
Schulte HM, Chrousos GP, Gold PW, et al: Continuous administration of synthetic ovine corticotropin-releasing factor in man: Physiological and pathophysiological implications. J Clinical Investigation 75:1781-1785, 1985 (Pubitemid 15237785)
-
(1985)
Journal of Clinical Investigation
, vol.75
, Issue.6
, pp. 1781-1785
-
-
Schulte, H.M.1
Chrousos, G.P.2
Gold, P.W.3
-
13
-
-
0029939878
-
Corticotropin-releasing factor decreases vasogenic brain edema
-
Tjuvajev J, Uehara H, Desai R, et al: Corticotropin-releasing factor decreases vasogenic edema. Cancer Res 56:1352-1360, 1996 (Pubitemid 26080979)
-
(1996)
Cancer Research
, vol.56
, Issue.6
, pp. 1352-1360
-
-
Tjuvajev, J.1
Uehara, H.2
Desai, R.3
Beattie, B.4
Matei, C.5
Zhou, Y.6
Kreek, M.-J.7
Koutcher, J.8
Blasberg, R.9
-
14
-
-
8344241192
-
The management of brain edema in brain tumors
-
DOI 10.1097/01.cco.0000142076.52721.b3
-
Kaal EC, Vecht CJ: The management of brain edema in brain tumors. Curr Opin Oncol 16:593-600, 2004 (Pubitemid 39482980)
-
(2004)
Current Opinion in Oncology
, vol.16
, Issue.6
, pp. 593-600
-
-
Kaal, E.C.A.1
Vecht, C.J.2
-
15
-
-
79959582372
-
Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models
-
Gamez I, Ryan RP, Reid LD, et al: Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models. Cancer Chemother Pharmacol 67:1415-1422, 2011
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 1415-1422
-
-
Gamez, I.1
Ryan, R.P.2
Reid, L.D.3
-
16
-
-
84875986930
-
Evidence of continued clinical benefit in patients who participated in an open-label, extended-use study of human corticotropin releasing factor (HCRF) in patients with cerebral edema who received HCRF for at least 6 months
-
O'Connor PC, Kroon H-A, Recht LD: Evidence of continued clinical benefit in patients who participated in an open-label, extended-use study of human corticotropin releasing factor (HCRF) in patients with cerebral edema who received HCRF for at least 6 months. Neuro-Oncology 12:iv38, 2010 (suppl 4)
-
(2010)
Neuro-Oncology
, vol.12
, Issue.SUPPL. 4
-
-
O'Connor, P.C.1
Kroon, H.-A.2
Recht, L.D.3
-
17
-
-
0014341457
-
Steroid myopathy: Clinical, histologic and cytologic observations
-
Afifi AK, Bergman RA, Harvey JC: Steroid myopathy: Clinical, histologic and cytologic observations. Johns Hopkins Med J 123:158-173, 1968
-
(1968)
Johns Hopkins Med J
, vol.123
, pp. 158-173
-
-
Afifi, A.K.1
Bergman, R.A.2
Harvey, J.C.3
-
19
-
-
0030975554
-
Steroid myopathy in cancer patients
-
Batchelor TT, Taylor LP, Thaler HT, et al: Steroid myopathy in cancer patients. Neurology 48:1234-1238, 1997 (Pubitemid 27240540)
-
(1997)
Neurology
, vol.48
, Issue.5
, pp. 1234-1238
-
-
Batchelor, T.T.1
Taylor, L.P.2
Thaler, H.T.3
Posner, J.B.4
DeAngelis, L.M.5
-
20
-
-
0025800020
-
Steroid-induced weakness in patients with primary brain tumors
-
Dropcho EJ, Soong S-J: Steroid-induced weakness in patients with primary brain tumors. Neurology 41:1235-1239, 1991
-
(1991)
Neurology
, vol.41
, pp. 1235-1239
-
-
Dropcho, E.J.1
Soong, S.-J.2
-
21
-
-
0002714896
-
Endocrine myopathies
-
Engel AG, Banker BQ (eds) New York, NY, McGraw-Hill
-
Ruff RL: Endocrine myopathies, in Engel AG, Banker BQ (eds): Myology: Basic and clinical. New York, NY, McGraw-Hill, 1986, pp 1871-1979
-
(1986)
Myology: Basic and Clinical
, pp. 1871-1979
-
-
Ruff, R.L.1
|